A Novel Approach Using FDG-PET/CT-Based Radiomics to Assess Tumor Immune Phenotypes in Patients With Non-Small Cell Lung Cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Novel Approach Using FDG-PET/CT-Based Radiomics to Assess Tumor Immune Phenotypes in Patients With Non-Small Cell Lung Cancer
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-11-17
DOI
10.3389/fonc.2021.769272
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
- (2021) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- Correlation Between Dual-Time-Point FDG PET and Tumor Microenvironment Immune Types in Non-Small Cell Lung Cancer
- (2021) Jianyuan Zhou et al. Frontiers in Oncology
- Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma
- (2020) Byeong-Joo Noh et al. BMC CANCER
- Introduction to Radiomics
- (2020) Marius E Mayerhoefer et al. JOURNAL OF NUCLEAR MEDICINE
- Utility of CT radiomics for prediction of PD‐L1 expression in advanced lung adenocarcinomas
- (2020) Jiyoung Yoon et al. Thoracic Cancer
- Performance of Multiparametric Functional Imaging and Texture Analysis in Predicting Synchronous Metastatic Disease in Pancreatic Ductal Adenocarcinoma Patients by Hybrid PET/MR: Initial Experience
- (2020) Jing Gao et al. Frontiers in Oncology
- Machine and deep learning methods for radiomics
- (2020) Michele Avanzo et al. MEDICAL PHYSICS
- Predicting response to radiotherapy in tumors with PET/CT: when and how?
- (2020) Li-Fang Shen et al. Translational Cancer Research
- Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy
- (2019) Min Zhang et al. Frontiers of Medicine
- Assessing PD-L1 Expression Level by Radiomic Features From PET/CT in Nonsmall Cell Lung Cancer Patients: An Initial Result
- (2019) Mengmeng Jiang et al. ACADEMIC RADIOLOGY
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- Dosiomics: Extracting 3D Spatial Features From Dose Distribution to Predict Incidence of Radiation Pneumonitis
- (2019) Bin Liang et al. Frontiers in Oncology
- Is it time to change our vision of tumor metabolism prior to immunotherapy?
- (2018) Fabio Grizzi et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Ability of FDG PET and CT radiomics features to differentiate between primary and metastatic lung lesions
- (2018) Margarita Kirienko et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Understanding the tumor immune microenvironment (TIME) for effective therapy
- (2018) Mikhail Binnewies et al. NATURE MEDICINE
- 2-Deoxy-2-[fluorine-18] fluoro-d-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma
- (2018) Kyoichi Kaira et al. EUROPEAN JOURNAL OF CANCER
- A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study
- (2018) Roger Sun et al. LANCET ONCOLOGY
- Diagnostic and prognostic value of baseline FDG PET/CT skeletal textural features in diffuse large B cell lymphoma
- (2017) Nicolas Aide et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1)
- (2016) Shingo Inaguma et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration
- (2016) C.-Y. Ock et al. CLINICAL CANCER RESEARCH
- Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery
- (2016) Egesta Lopci et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study
- (2016) Ziad Hijazi et al. LANCET
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
- (2016) Corey J Langer et al. LANCET ONCOLOGY
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests
- (2016) Andrew J Vickers et al. BMJ-British Medical Journal
- Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests
- (2016) Andrew J Vickers et al. BMJ-British Medical Journal
- Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
- (2016) Joseph McLaughlin et al. JAMA Oncology
- Classifying Cancers Based on T-cell Infiltration and PD-L1
- (2015) Michele W.L. Teng et al. CANCER RESEARCH
- Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
- (2015) Chih-Hao Chang et al. CELL
- Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status
- (2015) Jaemoon Koh et al. MODERN PATHOLOGY
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Impact of initial PET/CT staging in terms of clinical stage, management plan, and prognosis in 592 patients with non-small-cell lung cancer
- (2014) Satoshi Takeuchi et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Radiomics: Extracting more information from medical images using advanced feature analysis
- (2012) Philippe Lambin et al. EUROPEAN JOURNAL OF CANCER
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Criteria for Evaluation of Novel Markers of Cardiovascular Risk
- (2009) Mark A. Hlatky et al. CIRCULATION
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started